Last reviewed · How we verify
NASVAC
NASVAC is a therapeutic vaccine designed to stimulate immune responses against hepatitis B surface antigen (HBsAg) in chronic hepatitis B patients.
NASVAC is a therapeutic vaccine designed to stimulate immune responses against hepatitis B surface antigen (HBsAg) in chronic hepatitis B patients. Used for Chronic hepatitis B infection (Phase 3 development).
At a glance
| Generic name | NASVAC |
|---|---|
| Sponsor | Clinical Research Organization, Dhaka, Bangladesh |
| Drug class | Therapeutic vaccine |
| Target | Hepatitis B surface antigen (HBsAg) |
| Modality | Biologic |
| Therapeutic area | Virology / Hepatology |
| Phase | Phase 3 |
Mechanism of action
NASVAC combines recombinant hepatitis B surface antigen with immunomodulatory components to enhance T-cell and B-cell mediated immunity in chronically infected patients. The vaccine aims to restore immune control of HBV replication and potentially achieve functional cure (HBsAg loss) in combination with antiviral therapy or as monotherapy.
Approved indications
- Chronic hepatitis B infection (Phase 3 development)
Common side effects
- Injection site reactions
- Fever
- Fatigue
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |